Research notes

The note says Bharti hiked postpaid tariffs by Rs 50 across the board effective the same day, with postpaid accounting for nearly 8-12%.

The note says HUL raised detergent prices across Wheel, Surf Excel and Rin in October by 2.2% to 7.1% per dealer checks.

The note says Kalyan reported 26% y/y consolidated revenue growth in July-September, with India up 27% and international up 18%, and lists a positive derivative setup in Kalyan.

The note says an L&T unit secured a limited notice to proceed from DVC CIL Power for the main plant package of the 1,600 MW Chandrapura thermal power plant in Jharkhand.

The report expects 15% YoY revenue growth led by patient and test volumes with EBITDA margin improvement, naming it a strong performer.

The report expects 17% YoY revenue growth with volume-led gains and margin expansion, naming it a strong performer.

The report expects 20% YoY revenue growth but a decline in private label sales to impact margins, listing it as a muted performer.

The report flags numbers as not comparable due to the Quality Care Hospital merger, with strong reported growth but a cautious first integration quarter.

The report expects 17% YoY revenue growth but margin pressure from integration of low-margin acquired hospitals, listing it as a muted performer.

The report expects 19% YoY revenue growth from better occupancy and new bed additions, naming it a strong performer with margin improvement.

The report expects 26% YoY revenue growth and 55% YoY EBITDA growth driven by Small Molecule CDMO, naming it a strong performer despite its REDUCE rating.

The report expects 23% YoY revenue growth led by the CRDMO business, naming it a strong performer.

The report expects 14% YoY revenue growth led by CDMO and CHG businesses, with EBITDA margin expansion though PAT remains negative.

The report expects 11% YoY revenue growth with soft CMC business but strong CRO growth, with margin expansion expected.

The report expects 17% YoY revenue growth led by Custom Synthesis business, naming it a strong performer.

The report expects 27% YoY revenue growth but a sharp margin correction due to absence of gRevlimid and gMyrbetriq royalty fees, listing it as a muted performer.

The report notes 51% YoY revenue growth (not comparable due to JB Chemicals integration), with margin improvement from cost synergies but flattish PAT growth.

The report expects 11% YoY revenue growth driven by specialty scale-up and India growth, with EBITDA margin improving on cost controls.

The report expects 13% YoY revenue growth and margin expansion on better sales mix and cost controls, naming it a strong performer.

The report expects a 14% YoY EBITDA decline due to competition-led price erosion in Tolvaptan and gMyrbetriq, listing it as a muted performer.

The report expects 11% YoY revenue growth with gross margin expansion supporting EBITDA margin improvement.

The report expects 13% YoY revenue growth led by India chronic therapies and the Semaglutide launch, naming it among strong performers.

The report expects a 4% YoY revenue decline and a sharp EBITDA margin contraction due to absence of gRevlimid and price erosion, flagging it as a muted performer.

The report expects 18% YoY revenue growth driven by Lannett integration and Europe momentum, calling it among the strong performers this quarter.

The report expects 13% YoY revenue growth led by India formulations and Occlutech consolidation, but margins to stay under pressure from integration and higher costs.